AU2023261450A1 — Nucleoside drug for treating or preventing coronavirus infection, and use thereof
Assigned to Miracure Biotechnology Ltd · Expires 2024-11-14 · 2y expired
What this patent protects
The present invention relates to the technical field of medicines, and in particular to a nucleoside drug for treating or preventing coronavirus infection, and a use thereof. The present invention further relates to a method for preparing a prodrug of a nucleoside drug. Compared …
USPTO Abstract
The present invention relates to the technical field of medicines, and in particular to a nucleoside drug for treating or preventing coronavirus infection, and a use thereof. The present invention further relates to a method for preparing a prodrug of a nucleoside drug. Compared with other nucleoside drugs such as remdesivir for injection, the nucleoside drug of formula (I) or formula (II) provided in the present invention is more suitable for oral administration to individuals in need.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.